1. Detection of Multiple HPV Types in Liquid Biopsies of Cervical Neoplasia.
- Author
-
Herbst J, Vohl V, Krajina M, Leffers M, Kropidlowski J, Prieske K, Jaeger A, Oliveira Ferrer L, Schmalfeldt B, Goy Y, Burandt E, Pantel K, Vollmert C, Sartori A, Woelber L, Effenberger K, and Wikman H
- Subjects
- Humans, Female, Human Papillomavirus Viruses, Human papillomavirus 16 genetics, Human papillomavirus 18, Liquid Biopsy, DNA, Uterine Cervical Neoplasms diagnosis, Papillomavirus Infections diagnosis, Cell-Free Nucleic Acids
- Abstract
Background: More than 95% of cervical cancers and their precancerous lesions are caused by human papillomavirus (HPV). Cell-free (cf) HPV DNA detection in blood samples may serve as a monitoring tool for cervical cancer., Methods: In our methodological study, an HPV panel for simultaneous detection of 24 types using mass spectrometry-based analysis was developed for liquid biopsy approaches and tested on HPV positive cell lines, plasmid controls, and cervical high-grade squamous intraepithelial lesions (HSIL) in positive smear samples (n = 52). It was validated in cfDNA blood samples (n = 40) of cervical cancer patients., Results: The HPV panel showed proficient results in cell lines and viral plasmids with a limit of detection of 1 IU (international units)/µL for HPV16/18 and 10GE/µL for HPV11/31/33/39/45/51/52/58/59 and a specificity of 100% for the tested HPV types. In cervical smear samples, HPV DNA was detected with a sensitivity of 98.14%. The overall agreement between the new HPV panel and clinical records was 97.2% (κ = 0.84). In cervical cancer cfDNA, 26/40 (65.0%) tested positive for any HPV type, with most infections due to hrHPV (24/26). HPV positive samples were found in all FIGO stages, with the highest positivity ratio in FIGO III and IV. Even the lowest stage, FIGO I, had 12/23 (52.2%) patients with a positive HPV plasma status., Conclusions: This proof-of-concept paper shows that the described assay produces reliable results for detecting HPV types in a multiplex mass spectrometry-based assay in cervical smear and cfDNA with high specificity and sensitivity in both cohorts. The assay shows potential for liquid biopsy-based applications in monitoring cervical cancer progression., (© Association for Diagnostics & Laboratory Medicine 2024. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF